Wells Fargo & Company 89bio, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in 89bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 39,135 shares of ETNB stock, worth $325,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,135

Previous 55,679 29.71%

Holding current value

$325,994

Previous $445,000 35.06%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$7.36 - $9.66 $121,763 - $159,815	-16,544 Reduced 29.71%	39,135 $289,000
Q2 2024 Aug 13, 2024	SELL	$7.31 - $10.9 $335,053 - $499,601	-45,835 Reduced 45.15%	55,679 $445,000
Q1 2024 May 10, 2024	BUY	$8.13 - $13.77 $127,307 - $215,624	15,659 Added 18.24%	101,514 $1.18 Million
Q4 2023 Feb 09, 2024	SELL	$6.66 - $16.03 $501,604 - $1.21 Million	-75,316 Reduced 46.73%	85,855 $959,000
Q3 2023 Nov 13, 2023	BUY	$15.06 - $19.41 $99,652 - $128,435	6,617 Added 4.28%	161,171 $2.49 Million
Q2 2023 Aug 15, 2023	BUY	$14.15 - $22.03 $1.43 Million - $2.23 Million	101,130 Added 189.3%	154,554 $2.93 Million
Q1 2023 May 12, 2023	BUY	$10.48 - $16.94 $557,556 - $901,241	53,202 Added 23964.86%	53,424 $813,000
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $220 - $509	40 Added 21.98%	222 $2,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $377 - $875	125 Added 219.3%	182 $1,000
Q2 2022 Aug 12, 2022	SELL	$2.09 - $4.02 $175 - $337	-84 Reduced 59.57%	57 $0
Q1 2022 May 16, 2022	SELL	$3.45 - $14.99 $12,112 - $52,629	-3,511 Reduced 96.14%	141 $1,000
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $40,719 - $71,798	3,652 New	3,652 $48,000
Q3 2021 Nov 15, 2021	SELL	$14.91 - $21.31 $1,833 - $2,621	-123 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $41,964 - $67,452	-2,409 Reduced 95.14%	123 $2,000
Q1 2021 May 13, 2021	SELL	$20.22 - $26.73 $349,684 - $462,268	-17,294 Reduced 87.23%	2,532 $60,000
Q4 2020 Feb 09, 2021	BUY	$23.16 - $28.08 $363,866 - $441,164	15,711 Added 381.8%	19,826 $483,000
Q3 2020 Nov 05, 2020	BUY	$24.34 - $38.82 $1,533 - $2,445	63 Added 1.55%	4,115 $106,000
Q2 2020 Aug 13, 2020	BUY	$19.93 - $31.2 $28,420 - $44,491	1,426 Added 54.3%	4,052 $81,000
Q1 2020 May 14, 2020	BUY	$16.4 - $41.77 $43,066 - $109,688	2,626 New	2,626 $66,000

Others Institutions Holding ETNB

# of Institutions

158

Shares Held

108M

Call Options Held

73.6K

Put Options Held

1.19M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company 89bio, Inc. Transaction History